A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 9456
- Population
- ALL · 18 Years to 85 Years
- Duration
- 2020-06-03 to 2020-12-15
- Intervention
- Brolucizumab
- Comparator
- Not reported
- Outcomes measured
- Number of patient eyes with an Intraocular Inflammation (IOI) event during the first 6 months — Up to 6 months post bro…; Age — At the brolucizumab index date defined as the date of first brolucizumab injection; Gender information — At the brolucizumab index date defined as the date of first brolucizumab injection; Number of patients at various Patient Region — At the brolucizumab index date defined as the date of first brolucizumab…; Number of patients with Insurance type — At the brolucizumab index date defined as the date of first brolucizumab injec…; Number of patients with Laterality of wet Age-related macular degeneration (AMD) — At the brolucizumab index date defin…; Race/Ethnicity of the participants (patient level and eye level) — At the brolucizumab index date defined as the date o…; Number of eyes with the concurrent eye disease — Within 180 days prior to the index date (inclusive of the index date)…; Number of patient eyes with cataract status — 36-month period prior to the index date (inclusive of the index date) ( i…; Number of patient eyes with Concomitant ocular medications — 36-month period prior to the index date (inclusive of the…; Number of patient eyes with the history of ocular inflammation — 36-month period prior to the index date (inclusive of…; Number of patient eyes with prior Intraocular Inflammation (IOI) and/or prior Retinal vascular occlusion (RO) — 12 mont…; Number of patient eyes with the Provider specialty — At the brolucizumab index date defined as the date of first broluc…; Number of patient eyes with the previous ocular surgeries or procedures — 6 months prior to the index date ( index date…; Number of eyes treated with brolucizumab — At the brolucizumab index date defined as the date of first brolucizumab inj…; Number of patient eyes with Visual Acuity (VA) reading — At the brolucizumab index date defined as the date of first br…; Number of patient eyes with Anti-VEGF treatment-naive vs prior-treated — 36-month period prior to the index date (inclu…; Number of patient eyes with the prior treatment status — 36-month period prior to the index date (inclusive of the inde…; Number of different prior anti-VEGF agents — 36-month period prior to the index date (inclusive of the index date) ( in…; Number of prior anti-VEGF injections — 36-month period prior to the index date (inclusive of the index date) ( index da…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.